We observed that mTOR inhibition partially mitigates seizure severity when provided at the appropriate dose, which parallels studies in tuberous sclerosis complex (TSC), where mTOR-targeted therapies reduce but do not eliminate seizures [15,16,17]. The gene discussed is MTOR; the disease is tuberous sclerosis.